



The Challenge of MDR and XDR infections

Friday, 14th September 2018
Casa de la Convalescència,
Barcelona - Spain

www.fl-s-science.com/mdr-infections



Challenge of MDR and XDR infections

The rapid emerging resistant bacteria, poses a major healthcare and it is one of the main public health problems of our time. The cost of antibiotic resistance is enormous for the healthcare system and the community. It increases health costs by reducing the options to prevent and treat infections, leads to longer illnesses, medical complications, loss of protection for patients undergoing medical procedures and prolonged hospitalization; it inevitably leads to an increased mortality.

This workshop is an excellent learning and networking platform for healthcare professionals and researchers involved in the prevention and treatment of infectious diseases. The conference led by renowned experts, will provide a comprehensive overview of the epidemiology and management of multidrug resistant microorganisms and will go in depth analysis the most prominent and current issues of antibiotic resistance.



The challenge of MDR and XDR infections

Venue

Friday, 14th September 2018

Casa de la Convalescència

Outstanding building of modernist architecture.



© Casa Convalescència

Scientific Sponsorship



Accreditation

The “**The challenge of Multi-drug (MDR) and extensively-drug resistant (XDR) infections workshop.**” has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **6 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.



Program

Friday 14th September 2018

8.15 8.45	Breakfast and Registration	
08.45 09.00	Welcome	J.M. Miró
Overview on Multidrug Resistant Organisms		Chair: M.L. Pedro-Botet
09.00 10.30	The One Health perspective on Antimicrobial Resistance: The way forward	Bruno González-Zorn , Spain
	Antimicrobial stewardship: Effective implementation for improved clinical outcomes	José Miguel Cisneros , Spain
	New and emerging antibiotics: data and practical recommendations	Robert A. Bonomo , USA
	Overall discussion	
10.30 11.00	Coffee Break	
What antibiotics do we have when facing against invasive MRSA and VRE infections		Chairs: R. Cantón J. López-Contreras
11.00 12.30	MRSA management	José M. Miró , Spain
	VRE management	Cesar Arias . USA
	<i>Staphylococcus aureus</i> immunotherapy: from vaccines to antibodies	Rafael Mañez-Mendiluce , Spain (TBC)
	Overall discussion	
12.30 13.30	Lunch	



Program Friday 14th September 2018

Multidrug and extremely drug-resistant gram-negative bacilli: the storm is here		<i>Chair: J.M. Miró, M.A Domínguez</i>
13.30 15.00	Therapeutic challenge of multidrug resistant Enterobacteriaceae infections	J. Rodríguez Baño , Spain
	Multi-drug resistant <i>Pseudomonas aeruginosa</i>	JP. Horcajada , Spain
	Resistance to new beta-lactam-beta-lactamase inhibitor combinations: a new step in the multi-drug resistance?	Rafael Cantón , Spain
	Overall discussion	
15.00 15.30	Coffee Break	
Clostridium difficile and the influence of Microbiome in the pathogenesis of infectious diseases		<i>Chair: N. Sopena, G. Fernández</i>
15.30 17.30	<i>Clostridium difficile</i> , more difficult than ever	Benoit Guery , Switzerland
	In vitro model of the human colon	Christopher Rooney , UK
	The gut microbiome in infectious diseases: opportunities and challenges	Roger Paredes , Spain
	The need to re-address the duration of antibiotic treatment	Harald Seifert , Germany (TBC)
	Overall discussion	
17.30 17.45	Closing remarks	M.L. Pedro-Botet



SCIENTIFIC COMMITTEE



Bonaventura Clotet, Director IrsiCaixa. Head of Infectious Diseases, Hospital Universitari Germans Trias i Pujol. IrsiCaixa. UAB. UVIC-UCC Badalona, Spain.

Bonaventura Clotet, Specialized in Internal Medicine and Infectious Diseases. PhD in Medical Sciences. He is Head of the Infectious Diseases department, Director of the Retrovirology Laboratory “IrsiCaixa” Foundation at the Hospital Universitari Germans Trias i Pujol and President of the Foundation “Lluita contra la SIDA”. He is co-director of the HIVACAT project for the development of the AIDS vaccine. He is the director of the Chair of AIDS and Related Diseases at the University of Vic (UVic). In April 2016, Clotet was awarded with the ‘Creu de St. Jordi’ for being one of the most internationally renowned HIV researchers. Dr. Clotet has created 2 spin-offs from IrsiCaixa: AELIX Therapeutics for the development of a therapeutic vaccine for HIV infected patients and AlbaJuna Therapeutics for the development of an Immunoglobulin for curing & preventing HIV. He has more than 700 papers in international journals (Impact factor: >5.000 // H-index: 81)

**Bonaventura Clotet has received research support grants from MSD and Gilead Sciences, received honoraria or consultation fees from MSD and participated in a company sponsored speaker's bureau from Gilead Sciences.*






Rafael Cantón is the Head of the Clinical Microbiology Department at the University Hospital Ramón y Cajal (Madrid, Spain) and is associated Professor of Clinical Microbiology at School of Pharmacy at Complutense University (Madrid, Spain).

His research activity is developed within the Spanish Network for Research in Infectious Diseases (REIPI) and Institute Ramón y Cajal for Health Research (IRYCIS). His clinical and research work is focussed on antimicrobial susceptibility testing, mechanisms of antimicrobial resistance and interplay with dispersion of high-risk clones, and respiratory tract infections. He has published more than 430 articles in medical journals (H-index of 61 in 2018), 50 chapters in teaching books and has presented more than 850 abstracts at international and national congress and has given more than 500 conferences. He is currently Clinical Data Coordinator of the European Committee for Antimicrobial Susceptibility Testing (EUCAST) and member of the Spanish Antimicrobial Committee (COESANT). He is co-editor of the Clinical Microbiology Procedures of the SEIMC.

**Rafael Cantón has received research support grants from AstraZeneca and MSD and participated in a company sponsored speaker's bureau from AstraZeneca, MSD, Pfizer and Angelini.*




Vance Fowler, Vance Fowler, MD, MHS, Professor, Departments of Medicine and Molecular Genetics & Microbiology, Duke University Medical Center.

Dr. Fowler has over 2 decades of continuous support as PI from the NIH for clinical and translational research in *Staphylococcus aureus* and other bacterial infections. Dr. Fowler created the *S. aureus* Bacteremia Group, co-founded the International Collaboration on Endocarditis, and is the Communicating PI of the Antibacterial Resistance Leadership Group.

**Vance Fowler has received research support grants from NIH, Cerexa, Actavis, Allergan, Pfizer, MedImmune, ContraFect, Karius and Regeneron and received honoraria or consultation fees from Novartis, Achaogen, Astellas, Arsanis, Affinergy, Bayer, Cerexa, ContraFect, Debiopharm, Genetech, MedImmune, Medicines Co, NovaDigm, Theravance and XBiotech.*





José M. Miró is currently Senior Consultant of Infectious Diseases at the Hospital Clinic IDIBAPS of Barcelona, Associate Professor of Medicine at the University of Barcelona, and Director of the Master on AIDS of the University of Barcelona.

He is evaluating new antibiotics for the treatment of endocarditis caused by multi-drug resistant Gram positive bacteria and is doing epidemiological and prognostic studies with Spanish (GAMES) and International (ICE) cohorts. He is also conducting clinical trials on Staphylococcus aureus and Enterococcal bacteremia/endocarditis. He is also focusing on epidemiological studies in HIV cohorts, primary HIV-1 infection, tuberculosis and other opportunistic Infections, clinical trials in advanced patients and solid organ transplantation in HIV-1 infected patients. Dr. Miro is a researcher of EuroSIDA, COHERE, ART-CC and Euro-TB, co-chair of the PISCIS cohort and the Barcelona Site of the TB Trials Consortium of the CDC (Atlanta, GA). He is a member of the expert panels on the Spanish ART Guidelines, GESIDA, European (EACS) and American (NIH, CDC, IDSA) opportunistic infections panels, the European Society of Cardiology (ESC) and the American Heart Association (AHA) infective endocarditis panels. He has published more than 690 articles in peer-review journals (h-index 61).

**José M. Miró has received research support grants from Angelini, MSD, Novartis, Pfizer and ViiV Healthcare and received honoraria or consultation fees from Abbvie, BMS, Genentech, Gilead, Jansen, Medtronic, MSD, Novartis, Pfizer and ViiV Healthcare.*



Jesús Rodríguez-Baño, PhD, MD, FESCMID is President of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID).

Head of the Infectious Diseases Division at Hospital Universitario Virgen Macarena and Professor of Medicine at the University of Seville, Spain; Chair of the Spanish Network for Research in Infectious Diseases (REIPI); and member of the Scientific Advisory Board of the Joint Programme Initiative on Antimicrobial Resistance. He is author of more than 280 peer-reviewed articles and leader or partner in several European research projects; his areas of interest include antimicrobial resistance (clinical epidemiology, control and treatment) and healthcare-associated infections.

** Jesús Rodríguez-Baño has received honoraria or consultation fees from AstraZeneca*





Roger Paredes, HIV Physician at Hospital Germans Trias i Pujol and Head of the Microbial Genomics Group at the IrsiCaixa AIDS Research Institute, Barcelona, Spain.

Roger Paredes obtained an MD, PhD degree in Medicine and Surgery from the Autonomous University of Barcelona (UAB). He specialised in HIV resistance at the Brigham & Women's Hospital in Boston and Harvard Medical School, being funded by a post-doctoral scholarship from "la Caixa". He has demonstrated the clinical utility of new methods of sequencing HIV in both high- and low-income countries. He is a member of the WHO HIV Drug Resistance Strategy (ResNet) Steering Committee and of the International Antiviral Society-USA. He is co-author of the Rega algorithm for interpreting resistance to antiretrovirals and is a virologist for the EuroSIDA European cohort. His group has led pioneering research into the role of the gut microbiome in the pathogenesis of HIV infection and chronic inflammation.

**Roger Paredes has received research support grants and received honoraria or consultation fees from MSD and Gilead Sciences.*



Maria Lluisa Pedro-Botet, Section Head of Infectious Diseases Department at University Hospital " Germans Trias i Pujol". Investigator Member of CIBERes and AGAUR.

Dr. Pedro-Botet is specialized in Infectious Diseases, Respiratory Infections and Legionella. She is currently Professor and Chair of Medicine and member of the Grade of Medicine Committee at the Autonomous University of Barcelona's School of Medicine. She has been Principal or co-Investigator of 10 projects funded either by national or international grant agencies. Author of 91 papers in peer reviewed journals.

**Maria Lluisa Pedro-Botet declares no conflict of interest.*



This workshop is possible thanks to the support of:
Pfizer Inc.

